research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists may help or harm hair health, needing more research.
Search
for
Sort by
Research
210-240 / 458 results research Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia
Hair shedding is common in GLP-1 users, affecting treatment adherence.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
research Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: Current Evidence and Potential Mechanisms
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
research The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study
GLP-1 RA medications may be linked to hair loss.
research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
Newer GLP-1 drugs like semaglutide may cause hair loss.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
research 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
research Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.
research Alopecia and Semaglutide: Connecting the Dots for Patient Safety
Semaglutide may cause hair loss, but more research is needed to confirm this.
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research THE VICIOUS CYCLE OF POLYCYSTIC OVARY SYNDROME AND BINGE EATING DISORDER: A REVIEW OF METABOLIC, PSYCHOLOGICAL, AND IATROGENIC PATHWAYS
PCOS and BED are linked, needing new treatment approaches focusing on mental health and eating habits.
research Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
Effective weight loss during pregnancy is crucial for better maternal and fetal health.
research CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME
PCOS is best managed with personalized lifestyle changes, medications, and sometimes surgery.
research INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
PCOS treatment should be personalized based on individual symptoms and health goals.
research Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
Hair loss from weight-loss treatments is usually temporary and reversible.
research Abstracts from the 2024 WDS Forum - virtual option
5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.
research Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.